Slate Path Capital’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-818,042
| Closed | -$69.5M | – | 34 |
|
|
2019
Q4 | $69.5M | Sell |
818,042
-2,876,958
| -78% | -$192M | 3.74% | 12 |
|
|
2019
Q3 | $185M | Buy |
3,695,000
+150,000
| +4% | +$5.98M | 12.23% | 3 |
|
|
2019
Q2 | $129M | Buy |
3,545,000
+1,375,000
| +63% | +$44.9M | 5.8% | 5 |
|
|
2019
Q1 | $60.7M | Buy |
2,170,000
+95,000
| +5% | +$2.24M | 4.91% | 9 |
|
|
2018
Q4 | $39.7M | Buy |
2,075,000
+80,000
| +4% | +$1.86M | 4.48% | 9 |
|
|
2018
Q3 | $59.7M | Buy |
1,995,000
+265,000
| +15% | +$9.98M | 8.01% | 7 |
|
|
2018
Q2 | $63.5M | Hold |
1,730,000
| – | – | 4.8% | 10 |
|
|
2018
Q1 | $57M | Hold |
1,730,000
| – | – | 3.64% | 11 |
|
|
2017
Q4 | $47.3M | Buy |
1,730,000
+620,000
| +56% | +$19.1M | 4.65% | 9 |
|
|
2017
Q3 | $41.1M | Buy |
1,110,000
+565,000
| +104% | +$20.8M | 2.16% | 16 |
|
|
2017
Q2 | $20.7M | Sell |
545,000
-135,000
| -20% | -$6.01M | 0.79% | 15 |
|
|
2017
Q1 | $33.3M | Buy |
+680,000
| New | +$31M | 1.63% | 13 |
|
|
2016
Q1 | – | Sell |
-570,000
| Closed | -$21.3M | – | 15 |
|
|
2015
Q4 | $21.3M | Buy |
+570,000
| New | +$21.5M | 2.3% | 10 |
|
|
2015
Q1 | – | Sell |
-689,455
| Closed | -$19.1M | – | 17 |
|
|
2014
Q4 | $19.1M | Sell |
689,455
-385,545
| -36% | -$9.55M | 1.33% | 14 |
|
|
2014
Q3 | $24M | Buy |
+1,075,000
| New | +$27.3M | 1.08% | 18 |
|
Other funds holding MDCO
Slate Path Capital's MDCO Position: Q1 2020 in Review
Slate Path Capital sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 818,042 shares — an estimated $69.5M sold.
Slate Path Capital first reported a position in MDCO in Q3 2014 and held it in 15 quarters. The position peaked at $185M in Q3 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Slate Path Capital reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Slate Path Capital sold 818,042 Medicines Co shares in Q1 2020, an estimated $69.5M.
- Slate Path Capital first reported a position in Medicines Co in Q3 2014 and held it in 15 quarters.
- Slate Path Capital's Medicines Co position peaked at $185M in Q3 2019.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Slate Path Capital's 13F filing for Q1 2020, filed 15 May 2020.